Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hangzhou Coco Healthcare Products Co.,Ltd. (301009.SZ)
Hangzhou, CN
Hangzhou Coco Healthcare Products Co.,Ltd. is a Chinese enterprise dedicated to the innovation, manufacturing, and distribution of products across three main categories: baby care, adult incontinence, and pet hygiene. Its extensive portfolio of adult incontinence solutions features items such as adult diapers, pull-up pants, nursing pads, maternity towels, and menstrual pants, alongside a variety of general absorbent towels and specialized absorbent pads for men. Established in 2001, the company was initially known as Hangzhou Qiaozi Paper Industry Co.,Ltd. before adopting its current name, Hangzhou Coco Healthcare Products Co.,Ltd., in December 2011. Its operations are based in Hangzhou, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.23% | -6.98% | -15.04% | -27.55% | -30.28% | -24.29% | -37.58% | -19.46% | -62.86% | -62.86% | -62.86% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-12 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Household & Personal Products: +3.3%+6.7% ★ Q1'26: +4.0% (vs Q1'25)
-
EPS growth Household & Personal Products: +8.8%+16.7% ★ Q1'26: -89.8% (vs Q1'25)
-
FCF margin FCF growth · Household & Personal Products: +44.8%+5.6% Q1'26: -9.9% (vs Q1'25)
-
EBIT margin Household & Personal Products: +9.9%+3.6% Q1'26: +1.4% (vs Q1'25)
-
ROIC Household & Personal Products: +8.2%+6.3% Q1'26: +2.2% (vs Q1'25)
-
Share dilution Household & Personal Products: +0.2%-0.7% ★ Q1'26: -0.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Household & Personal Products: -0.51×1.98× ★ Q1'26: 10.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
1.31B
est.
|
1.19B
est: 1.23B (-3.3%)
|
1.19B
est: 1.05B (+13.4%)
|
1.08B
est: 1.05B (+3.4%)
|
1.08B
est: 1.07B (+1.0%)
|
1.15B
est: 1.14B (+0.5%)
|
1.23B
1.23B – 1.23B
+7.4% YoY
|
1.33B
1.33B – 1.33B
+7.9% YoY
|
| EBITDA |
113.68M
est.
|
93.07M
est: 106.34M (-12.5%)
|
4.50M
est: 86.80M (-94.8%)
|
74.60M
est: 86.80M (-14.1%)
|
88.11M
est: 68.99M (+27.7%)
|
103.79M
est: 73.95M (+40.4%)
|
79.43M
79.43M – 79.43M
+7.4% YoY
|
85.71M
85.71M – 85.71M
+7.9% YoY
|
| EBIT |
50.90M
est.
|
44.49M
est: 47.61M (-6.5%)
|
-55.23M
est: 41.73M (-232.3%)
|
20.88M
est: 41.73M (-50.0%)
|
33.63M
est: 16.57M (+103.0%)
|
41.61M
est: 17.76M (+134.3%)
|
19.07M
19.07M – 19.07M
+7.4% YoY
|
20.58M
20.58M – 20.58M
+7.9% YoY
|
| Net Income |
38.97M
est.
|
39.75M
est: -38.97M (+202.0%)
|
-43.13M
est: 24.70M (-274.6%)
|
20.18M
est: 24.70M (-18.3%)
|
31.17M
est: 30.96M (+0.7%)
|
36.12M
est: 33.54M (+7.7%)
|
41.28M
41.28M – 41.28M
+23.1% YoY
|
46.44M
46.44M – 46.44M
+12.5% YoY
|
| SGA |
107.53M
est.
|
127.85M
est: 100.58M (+27.1%)
|
125.51M
est: 114.47M (+9.6%)
|
135.44M
est: 114.47M (+18.3%)
|
165.35M
est: 125.92M (+31.3%)
|
112.39M
est: 134.97M (-16.7%)
|
144.97M
144.97M – 144.97M
+7.4% YoY
|
156.44M
156.44M – 156.44M
+7.9% YoY
|
| EPS |
0.15
est.
|
0.17
est: -0.15 (+213.3%)
|
-0.16
est: 0.10 (-268.3%)
|
0.07
est: 0.10 (-26.4%)
|
0.12
est: 0.12 (+0.0%)
|
0.14
est: 0.13 (+7.7%)
|
0.16
0.16 – 0.16
+23.1% YoY
|
0.18
0.18 – 0.18
+12.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | B- | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | B- | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | B- | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | B- | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | B- | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | B- | 2/5 | 2/5 | 2/5 | 3/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 2/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 2/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chaonan Li | Deputy GM & Financial Director | — | female |
| Jianjian Ding | Accounting Supervisor | — | — |
| Liwei Jin | Chief Executive Officer, Chairman of the Board & Acting Secretary of the Board of Directors | — | male |
| Zhongying Zhou | Deputy GM & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 301009.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
